Palvella Therapeutics, Inc.(PVLA)Earnings, Financials & Key RatiosPalvella Therapeutics, Inc. (PVLA) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's reliance on capital markets is evidenced by a $10.9 million quarterly free cash flow burn and the absence of any revenue-generating activities to offset its $15.8 million net loss in 2026Q1.
Palvella Therapeutics, Inc. (PVLA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Palvella Therapeutics, Inc. (PVLA) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $1.20vs $0.95-26.3% | — |
| Q2 2026 | Mar 31, 2026 | $1.08vs $0.91-18.5% | — |
| Q4 2025 | Nov 11, 2025 | $1.03vs $0.85-21.2% | — |
| Q3 2025 | Aug 14, 2025 | $0.86vs $0.78-10.3% | — |
Recent stock market news and headlines for Palvella Therapeutics, Inc. (PVLA)
Brings more than 25 years of experience advancing and commercializing high-impact therapies for serious diseases, including those with limited or no approved treatment options
FDA's rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed modules of the NDA before the full application is submitted
4,302 common shares were exercised and sold on June 17, 2026, for $476,000 at a weighted average price of around $110.73 per share. This was a derivative transaction involving the exercise and immediate sale of options.
FDA's rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed sections of the NDA before the full application is submitted
Key metrics vs top competitors for Palvella Therapeutics, Inc. (PVLA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $145.70 | $1.72B | -39.27 | — | — | -92.1% | — | |
| $74.90 | $1.46B | -7.70 | -43.89% | -284.18% | -87% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $5.38 | $1.32B | -20.69 | 22.09% | -13.58% | -38.11% | — | |
| $4.07 | $444.42M | -2.02 | — | — | -70.79% | — |
Palvella Therapeutics, Inc. (PVLA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Palvella Therapeutics, Inc. (PVLA) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 20, 2026·SEC
May 15, 2026·SEC
May 13, 2026·SEC
Get notified when PVLA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Palvella Therapeutics, Inc. (PVLA) stock FAQ — growth, dividends, profitability & financials explained
Palvella Therapeutics, Inc. (PVLA) reported a net loss of $49.3M for fiscal year 2025.
Palvella Therapeutics, Inc. (PVLA) has a return on equity (ROE) of -92.1%. Negative ROE indicates the company is unprofitable.
Palvella Therapeutics, Inc. (PVLA) had negative free cash flow of $29.1M in fiscal year 2025, likely due to heavy capital investments.
